These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 11599156)

  • 1. [Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes. Pharmacoeconomic analysis of cost-effectiveness].
    Costa Pinel B; Belmonte Serrano M; Páez Vives F; Sabaté Obiol A; Estopá Sánchez A; Borrás Borrás J
    Rev Clin Esp; 2001 Aug; 201(8):448-54. PubMed ID: 11599156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group.
    Heller SR; Amiel SA; Mansell P
    Diabetes Care; 1999 Oct; 22(10):1607-11. PubMed ID: 10526722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
    Ahmed AB; Mallias J; Home PD
    Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.
    Lalli C; Ciofetta M; Del Sindaco P; Torlone E; Pampanelli S; Compagnucci P; Cartechini MG; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1999 Mar; 22(3):468-77. PubMed ID: 10097931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.
    Ciofetta M; Lalli C; Del Sindaco P; Torlone E; Pampanelli S; Mauro L; Chiara DL; Brunetti P; Bolli GB
    Diabetes Care; 1999 May; 22(5):795-800. PubMed ID: 10332684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Insulin Lispro (Lys B28, Pro B29) treatment in adolescents and young people with type 1 diabetes].
    Tuset Castellano MJ; Martínez Badás I; Alonso Blanco M; Barrio Castellanos R
    An Esp Pediatr; 2000 Apr; 52(4):334-8. PubMed ID: 11003924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.
    Pfützner A; Küstner E; Forst T; Schulze-Schleppinghoff B; Trautmann ME; Haslbeck M; Schatz H; Beyer J
    Exp Clin Endocrinol Diabetes; 1996; 104(1):25-30. PubMed ID: 8750567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.
    Annuzzi G; Del Prato S; Arcari R; Bellomo Damato A; Benzi L; Bruttomesso D; Calderini MC; Coscelli C; Fedele D; Galluzzo A; Giordano M; Giorgino R; Lapolla A; Orsini P; Pagano G; Santoro D; Riccardi G
    Nutr Metab Cardiovasc Dis; 2001 Jun; 11(3):168-75. PubMed ID: 11590992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia.
    Reviriego J; Gomis R; Marañés JP; Ricart W; Hudson P; Sacristán JA
    Int J Clin Pract; 2008 Jul; 62(7):1026-32. PubMed ID: 18489577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of type 1 diabetes with insulin lispro during Ramadan.
    Kadiri A; Al-Nakhi A; El-Ghazali S; Jabbar A; Al Arouj M; Akram J; Wyatt J; Assem A; Ristic S
    Diabetes Metab; 2001 Sep; 27(4 Pt 1):482-6. PubMed ID: 11547222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
    Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
    Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus.
    Dunn CJ; Plosker GL
    Pharmacoeconomics; 2002; 20(14):989-1025. PubMed ID: 12403639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group.
    Gale EA
    Diabet Med; 2000 Mar; 17(3):209-14. PubMed ID: 10784225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lispro insulin as premeal therapy in type 1 diabetes: comparison with Humulin R.
    Daniels AR; Bruce R; McGregor L
    N Z Med J; 1997 Nov; 110(1056):435-8. PubMed ID: 9418839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.